Gabriele Ricci Biography and Net Worth

Insider of Takeda Pharmaceutical

Gabriele Ricci is the chief data and technology officer of Takeda. He was appointed to this role in February 2022 and leads the transformation of Takeda’s Data, Digital and Technology division.

Gabriele joined Takeda in 2019 as head of Plasma-Derived Therapies IT, during which he drove initiatives to meet the large and growing demand for plasma-derived products, with highly specialized services that require strategic capacity, innovative business models, dedicated R&D and agile supply allocation on a global scale. Prior to joining Takeda, Gabriele served as head of Digital Health and Emerging Technology at Shire, where he leveraged new and emerging technologies to optimize internal operations and deliver differentiated patient and customer experiences.

Gabriele has also served as Shire’s head of Technical Operations IT and held leadership positions at Novartis, Johnson & Johnson and Bristol-Myers Squibb. Gabriele brings more than 18 years of information technology and engineering expertise in the life sciences industry and sits on several advisory boards for non-profit organizations focused on digital, life sciences and manufacturing.

Gabriele holds an MBA from the MIB Trieste School of Management and a bachelor’s degree in engineering from the University of Rome Tor Vergata.

What is Gabriele Ricci's net worth?: The estimated net worth of Gabriele Ricci is at least $2.99 million as of August 10th, 2026. Ricci owns 171,654 shares of Takeda Pharmaceutical stock worth more than $2,992,787 as of August 13th. This net worth approximation does not reflect any other investments that Ricci may own. Learn More about Gabriele Ricci's net worth.
How do I contact Gabriele Ricci?: The corporate mailing address for Ricci and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Gabriele Ricci's contact information.
Has Gabriele Ricci been buying or selling shares of Takeda Pharmaceutical?: Over the course of the past ninety days, Gabriele Ricci has sold $429,004.80 of Takeda Pharmaceutical stock. Most recently, Gabriele Ricci sold 25,088 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $429,004.80. Following the completion of the sale, the insider now directly owns 171,654 shares of the company's stock, valued at $2,935,283.40. Learn More on Gabriele Ricci's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Lauren Duprey (Chief Transformation Officer), Samaan Farajallah (Insider), Anne Furney (General Counsel), Deidre Greenway (Insider), Riad Ibrahim (Insider), Julie Kim (Representative Director – President and CEO), Agosti Pignagnoli (Insider), Giles Platford (President, International Business Unit), Gabriele Ricci (Insider), and Elaine Shannon (President, Global Supply & Quality). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 444,100 shares worth more than $7,594,110.00. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Gabriele Ricci Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	25,088	$17.10	$429,004.80	171,654

Gabriele Ricci Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.38

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

358,604 shs

Average Volume

3,167,810 shs

Market Capitalization

$55.80 billion

P/E Ratio

51.23

Dividend Yield

2.75%

Beta

N/A